| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 25.8 | 70.6 |
| Net income | -101.2 | -34.6 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -63.5% |
|---|---|
| Operating margin | -401.8% |
10-Q filed with the SEC, NASDAQ: VRDN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Viridian Therapeutics, Inc.\DE: key numbers
- Share price
- $29.80Close, Nov 16
- Market cap
- $3.38B
- Shares outstanding
- 113.56MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Viridian Therapeutics, Inc.\DE
All →Viridian Therapeutics, Inc.\DE Clinical Trial Data
Viridian Therapeutics announced positive Phase 1 clinical trial results for VRDN-008, a half-life extended FcRn inhibitor, which demonstrated a 74% peak reduction in IgG and a half-life 5-6 times longer than first-generation fragments. The data supports a potential best-in-class every-eight-week subcutaneous dosing regimen, and the company plans to initiate a pivotal trial in myasthenia gravis in mid-2027.
Viridian Therapeutics Earnings Call: Key Takeaways
Viridian Therapeutics reported a strong LUMVO launch with $24.7 million in revenue, treating over 100 patients in its first quarter, while maintaining a robust $955 million cash position for future pipeline development.
- Call
- Nov 4, 2026, 8:00 AM ET
Viridian Therapeutics, Inc.\DE Financial Results
Viridian Therapeutics reported third quarter 2026 financial results, highlighted by $24.7 million in net product revenue from the launch of Lumvoa (veligrotug-vvze). The company remains on track for a BLA submission for elegrobart in Q1 2027 and expects Phase 1 data for VRDN-008 in Q4 2026.
“We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations. These strong early results are a testament to Lumvoa’s compelling clinical profile, the extraordinary execution of our Commercial and Medical teams, and the incredible support of our broader organization.”
Steve Mahoney, President and Chief Executive Officer